COLLABORATIVE DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT BY AND BETWEEN SYNTA PHARMACEUTICALS CORP. and SMITHKLINE BEECHAM CORPORATION (d/b/a GLAXOSMITHKLINE) October 8, 2007Collaborative Development, Commercialization and License Agreement • March 20th, 2008 • Synta Pharmaceuticals Corp • Pharmaceutical preparations • New York
This COLLABORATIVE DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of October 8, 2007 (the “Execution Date”) and effective as of the Effective Date (as defined below), by and between Synta Pharmaceuticals Corp., a Delaware corporation with offices at 45 Hartwell Avenue, Lexington, Massachusetts 02421 (“SYNTA”), and SmithKline Beecham Corporation (doing business as GlaxoSmithKline), a Pennsylvania corporation with offices at One Franklin Plaza, Philadelphia, Pennsylvania 19101 (“GSK”). Each of GSK and SYNTA is sometimes referred to individually herein as a “Party” and collectively as the “Parties.”
SYNTA LETTERHEAD] AMENDMENT TO CONSULTING AGREEMENTConsulting Agreement • March 20th, 2008 • Synta Pharmaceuticals Corp • Pharmaceutical preparations
THIS AMENDMENT (“Amendment”) is made as of March 23, 2007 (the “Effective Date”) by and between Synta Pharmaceuticals Corp., a Delaware corporation with a principal place of business at 45 Hartwell Avenue, Lexington, MA 02421 (“Synta”) and Lan Bo Chen, Ph.D. (“Consultant”) with a principal place of business at 184 East Emerson Rd., Lexington, MA 02420.
FIRST AMENDMENT TO LEASELease Agreement • March 20th, 2008 • Synta Pharmaceuticals Corp • Pharmaceutical preparations
FIRST AMENDMENT TO LEASE dated as of this 7th day of September, 2007 by and between MORTIMER B. ZUCKERMAN AND EDWARD H. LINDE, Trustees of 91 Hartwell Avenue Trust under Declaration of Trust dated September 28, 1981 filed with the Middlesex South Registry as Document No. 616455 as amended by instruments dated December 10, 1984 and April 17, 1991 respectively filed with said Registry District as Document Nos. 675674 and 844541 but not individually (“Landlord”) and SYNTA PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”).
NON-QUALIFIED STOCK OPTION AGREEMENT 75,000 SHARES OF COMMON STOCK,Non-Qualified Stock Option Agreement • March 20th, 2008 • Synta Pharmaceuticals Corp • Pharmaceutical preparations • Delaware
This Agreement, which includes the terms and conditions attached hereto, does not set forth all of the terms and conditions of the Plan, which is hereby incorporated into and made a part of this Agreement by reference. Any terms used and not defined herein have the same meanings as in the Plan. The Non-Employee Director acknowledges that he or she has received a copy of the Plan from the Company and has carefully read the terms and conditions of the Plan and the attached terms and conditions which make up a part of this Agreement.
